Insight Molecular Diagnostics (IMDX) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Q3 2025 value amounting to -$0.34.
- Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) rose 6530.61% to -$0.34 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.88, marking a year-over-year increase of 4268.29%. This contributed to the annual value of -$4.67 for FY2024, which is 112111.54% down from last year.
- Per Insight Molecular Diagnostics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.34 for Q3 2025, which was up 6530.61% from -$0.3 recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) registered a high of $0.0 during Q1 2023, and its lowest value of -$8.16 during Q4 2022.
- Moreover, its 4-year median value for EPS (Weighted Average and Diluted) was -$0.89 (2024), whereas its average is -$1.37.
- In the last 5 years, Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) skyrocketed by 10073.64% in 2023 and then tumbled by 13764215.15% in 2024.
- Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) (Quarter) stood at -$8.16 in 2022, then skyrocketed by 90.07% to -$0.81 in 2023, then plummeted by 217.63% to -$2.57 in 2024, then skyrocketed by 86.78% to -$0.34 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.34 in Q3 2025, compared to -$0.3 in Q2 2025 and -$0.26 in Q1 2025.